Supplemental material
Human Vaccines & Immunotherapeutics
Volume 18, 2022 - Issue 1
Pneumococcal – Research Paper
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU)
Randall Severancea Synexus Clinical Research, Chandler, AZ, USA
https://orcid.org/0000-0003-1580-5410View further author information
https://orcid.org/0000-0003-1580-5410View further author information, , Ron Daganc Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israelhttps://orcid.org/0000-0002-8888-1046View further author information
https://orcid.org/0000-0002-8888-1046View further author information, , , , , , Katrina M. Noland Merck & Co., Inc., Kenilworth, NJ, USAhttps://orcid.org/0000-0001-5030-7930View further author information
https://orcid.org/0000-0001-5030-7930View further author information, , Luwy K. Museyd Merck & Co., Inc., Kenilworth, NJ, USAhttps://orcid.org/0000-0001-5484-7037View further author information
https://orcid.org/0000-0001-5484-7037View further author information, Ulrike K. Buchwaldd Merck & Co., Inc., Kenilworth, NJ, USACorrespondence[email protected]
https://orcid.org/0000-0002-6671-0115View further author information
https://orcid.org/0000-0002-6671-0115View further author information & for the V114-021 (PNEU-FLU) Study Group show all